Bollard Group’s Nurix Therapeutics NRIX Stock Holding History

Bollard Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-122,782	Closed	-$1.4M	–	288
2025 Q2	$1.4M	Buy	+122,782	New	+$1.33M	0.03%	107

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bollard Group's NRIX Position: Q3 2025 in Review

Bollard Group sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 122,782 shares — an estimated $1.4M sold.

Bollard Group first reported a position in NRIX in Q2 2025 and held it in 1 quarter. The position peaked at $1.4M in Q2 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

Bollard Group reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
Bollard Group sold 122,782 Nurix Therapeutics shares in Q3 2025, an estimated $1.4M.
Bollard Group first reported a position in Nurix Therapeutics in Q2 2025 and held it in 1 quarter.
Bollard Group's Nurix Therapeutics position peaked at $1.4M in Q2 2025.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.